Diplomat Pharmacy Inc (DPLO) Expected to Post Earnings of $0.24 Per Share

Share on StockTwits

Equities research analysts expect Diplomat Pharmacy Inc (NYSE:DPLO) to report earnings of $0.24 per share for the current quarter, Zacks Investment Research reports. Six analysts have made estimates for Diplomat Pharmacy’s earnings, with estimates ranging from $0.22 to $0.27. Diplomat Pharmacy posted earnings of $0.18 per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 33.3%. The firm is expected to issue its next quarterly earnings report after the market closes on Monday, February 25th.

On average, analysts expect that Diplomat Pharmacy will report full year earnings of $0.81 per share for the current fiscal year, with EPS estimates ranging from $0.78 to $0.84. For the next financial year, analysts anticipate that the company will post earnings of $0.86 per share, with EPS estimates ranging from $0.77 to $1.02. Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that follow Diplomat Pharmacy.

Several research firms have recently weighed in on DPLO. Zacks Investment Research downgraded shares of Diplomat Pharmacy from a “hold” rating to a “strong sell” rating in a research note on Tuesday, November 27th. ValuEngine downgraded shares of Diplomat Pharmacy from a “hold” rating to a “sell” rating in a research note on Tuesday, November 6th. William Blair downgraded shares of Diplomat Pharmacy from an “outperform” rating to a “market perform” rating in a research note on Monday, January 7th. Robert W. Baird downgraded shares of Diplomat Pharmacy from a “neutral” rating to an “underperform” rating and decreased their price target for the stock from $22.00 to $10.00 in a research note on Wednesday, November 7th. Finally, Mizuho decreased their price target on shares of Diplomat Pharmacy to $18.00 and set a “neutral” rating on the stock in a research note on Friday, November 9th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and five have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $21.25.

Several large investors have recently bought and sold shares of DPLO. Vanguard Group Inc raised its stake in Diplomat Pharmacy by 4.0% during the third quarter. Vanguard Group Inc now owns 5,461,715 shares of the company’s stock worth $106,011,000 after purchasing an additional 209,939 shares during the period. Wells Fargo & Company MN raised its stake in Diplomat Pharmacy by 7.8% during the third quarter. Wells Fargo & Company MN now owns 95,621 shares of the company’s stock worth $1,856,000 after purchasing an additional 6,898 shares during the period. Quantbot Technologies LP purchased a new position in Diplomat Pharmacy during the third quarter worth about $696,000. Louisiana State Employees Retirement System raised its stake in Diplomat Pharmacy by 15.3% during the third quarter. Louisiana State Employees Retirement System now owns 24,900 shares of the company’s stock worth $483,000 after purchasing an additional 3,300 shares during the period. Finally, Dynamic Technology Lab Private Ltd purchased a new position in Diplomat Pharmacy during the third quarter worth about $240,000. 81.89% of the stock is currently owned by hedge funds and other institutional investors.

DPLO traded up $0.32 during midday trading on Monday, hitting $13.42. 373,232 shares of the company traded hands, compared to its average volume of 648,846. The company has a quick ratio of 0.66, a current ratio of 0.95 and a debt-to-equity ratio of 0.58. The company has a market cap of $989.71 million, a price-to-earnings ratio of 15.98 and a beta of 0.98. Diplomat Pharmacy has a 52-week low of $12.30 and a 52-week high of $28.74.

Diplomat Pharmacy Company Profile

Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.

See Also: What does the Dow Jones Industrial Average (DJIA) measure?

Get a free copy of the Zacks research report on Diplomat Pharmacy (DPLO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Orbis Token  Hits Market Cap of $145,138.00
Orbis Token Hits Market Cap of $145,138.00
Monarch Partners Asset Management LLC Increases Position in Old Line Bancshares, Inc.
Monarch Partners Asset Management LLC Increases Position in Old Line Bancshares, Inc.
Monarch Partners Asset Management LLC Purchases New Holdings in Innovative Industrial Properties Inc
Monarch Partners Asset Management LLC Purchases New Holdings in Innovative Industrial Properties Inc
Opus Capital Group LLC Boosts Holdings in SYNNEX Co.
Opus Capital Group LLC Boosts Holdings in SYNNEX Co.
National Bank Financial Weighs in on Canadian Western Bank’s Q3 2019 Earnings
National Bank Financial Weighs in on Canadian Western Bank’s Q3 2019 Earnings
CIELO S A/S  To Go Ex-Dividend on February 21st
CIELO S A/S To Go Ex-Dividend on February 21st


Leave a Reply

© 2006-2019 Ticker Report